Recently, novel FASN inhibitors (TVB-3166 and TVB-2640) have shown significant anticancer potential and lower systemic toxicity in BC, ovarian cancer, non-small cell lung cancer, and colorectal cancer. Here, FASN is linked to breast cancer.